Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial

INTRODUCTIONWe assessed a genetic risk score for Alzheimer's disease (AD-GRS) and apolipoprotein E (APOE4) in an exploratory neuroimaging substudy of the FINGER trial.METHODS1260 at-risk older individuals without dementia were randomized to multidomain lifestyle intervention or health advice. N = 126 participants underwent magnetic resonance imaging (MRI), and N = 47 positron emission tomography (PET) scans (Pittsburgh Compund B [PiB], Fluorodeoxyglucose) at baseline; N = 107 and N = 38 had repeated 2-year scans.RESULTSThe APOE4 allele, but not AD-GRS, was associated with baseline lower hippocampus volume (beta = -0.27, p = 0.001), greater amyloid deposition (beta = 0.48, p = 0.001), 2-year decline in hippocampus (beta = -0.27, p = 0.01), total gray matter volume (beta = -0.25, p = 0.01), and cortical thickness (beta = -0.28, p = 0.003). In analyses stratified by AD-GRS (below vs above median), the PiB composite score increased less in intervention versus control in the higher AD-GRS group (beta = -0.60, p = 0.03).DISCUSSIONAD-GRS and APOE4 may have different impacts on potential intervention effects on amyloid, that is, less accumulation in the higher-risk group (AD-GRS) versus lower-risk group (APOE).Highlights First study of neuroimaging and AD genetics in a multidomain lifestyle intervention. Possible intervention effect on brain amyloid deposition may rely on genetic risk. AD-GRS and APOE4 allele may have different impacts on amyloid during intervention.